Autopsy report · NCT05709821

IMM60 and Pembrolizumab in Melanoma and NSCLC

“Prioritization of other pipeline assets. No safety or efficacy issues were observed.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 10 months before it started.
• Ran for about 5 months before it stopped.
• 1 participant enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1, Phase 2

Sponsor

iOx Therapeutics

Sponsor type

Industry

Conditions

Non-small Cell Lung Cancer; Melanoma

Interventions

IMM60; Pembrolizumab

Participants

1

Sites

14

Countries

Spain, United Kingdom, United States

Trials that died the same way

• Non-alcoholic Steatohepatitis Registry Platform Study
  “Following a reassessment of the company's pipeline priorities, the sponsor has elected to discontinue this project prior to its planned completion” (61% match in meaning)
• A Biomarker Screening Protocol for Participants With Solid Tumors
  “Pipeline Reprioritization” (57% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.